srt-55 Antibody

What is Human Adenovirus 55 (HAdV55) and why are antibodies against it significant for research?

Human adenovirus type 55 (HAdV55) has re-emerged as a significant pathogen causing acute respiratory disease that can present as severe lower respiratory illness with potential fatal outcomes. Currently, there is no HAdV55 vaccine or treatment available for general use, making antibody research critically important . Anti-HAdV55 antibodies serve as valuable tools for fundamental research into virus-host interactions, diagnostic development, and potential therapeutic approaches. The significance of these antibodies lies in their ability to neutralize viral particles, potentially preventing infection and providing insights into immune responses against this pathogen. Understanding the structure-function relationship of these antibodies contributes to broader knowledge about viral immunology and may inform vaccine design strategies.

How are monoclonal antibodies against HAdV55 typically generated for research purposes?

The generation of monoclonal antibodies against HAdV55 typically follows a multi-step process beginning with immunization. Based on research protocols, this process involves:

• Immunization of female BALB/c mice (6-8 weeks old) via intraperitoneal injection using purified inactivated HAdV55 mixed with aluminum adjuvant, administered every 14 days for a total of 4 immunizations .

• Collection of blood samples to monitor antibody titers in mouse serum, with pre-immune samples serving as negative controls .

• Harvesting of spleen cells one week after the final booster immunization, followed by total RNA extraction and reverse transcription to cDNA .

• Construction of an scFv-phage display library derived from the immunized mice .

• Screening of the library using solid-phase methods with purified HAdV55 as the target antigen. The HAdV55-specific phage antibody library undergoes selection by coating purified HAdV55 in PBS onto immunotubes, followed by blocking with bovine serum albumin .

This methodological approach enables the isolation of specific monoclonal antibodies with potential for further development and characterization for research applications.

What key parameters should be evaluated when characterizing newly developed anti-HAdV55 antibodies?

When characterizing newly developed anti-HAdV55 antibodies, researchers should evaluate several critical parameters:

• Binding specificity: Assess the antibody's ability to recognize HAdV55 antigens through techniques such as ELISA, which provides quantitative measurements of antigen-antibody interactions .

• Neutralizing activity: Determine the antibody's capacity to prevent viral infection using virus micro-neutralization assays. This involves incubating serial dilutions of purified antibodies with standardized viral doses (typically 100 TCID50) before adding the mixture to susceptible cell lines such as A549 cells .

• Epitope identification: Employ Western blotting analysis and antigen-antibody molecular docking to identify specific antigenic epitopes recognized by the antibodies. This provides insights into the mechanism of neutralization and potential cross-reactivity .

• Thermal stability: Evaluate the antibody's stability under various temperature conditions to determine its suitability for different research and potential clinical applications .

• Cross-reactivity: Assess potential binding to other adenovirus serotypes to determine specificity for HAdV55 versus broader reactivity across adenovirus family members.

These characterization steps provide comprehensive insight into antibody performance and suitability for various research applications.

What are the optimal approaches for humanizing mouse-derived anti-HAdV55 antibodies to enhance their research and therapeutic potential?

The humanization of mouse-derived anti-HAdV55 antibodies requires sophisticated molecular engineering approaches to maintain binding specificity and neutralizing activity while reducing immunogenicity. Based on current research methodologies:

• Structural analysis: Use computational tools such as AlphaFold2 to predict antibody structures in both multimer and monomer modes. Select the top-ranked structure based on local distance difference test (pLDDT) scores as the foundation for humanization .

• CDR optimization: Apply the Chothia antibody-numbering scheme to renumber PDB residues, then use specialized software like the Antibody_H3 module in Rosetta 3 to optimize the complementarity determining region 3 (CDR3) conformation. This is crucial as CDR3 often plays the most significant role in antigen binding .

• Molecular docking simulation: Implement HADDOCK or similar tools to simulate antibody-antigen docking. Generate multiple conformations (e.g., 10,000 initial rigid body dockings) and select the top conformations with minimum energy scores for flexible refinement and energy minimization .

• Cluster analysis: Divide the refined conformations into different clusters according to Root Mean Square Deviation (RMSD) to identify optimal humanized variants .

• Experimental validation: Following in silico design, express the humanized variants in appropriate expression systems such as FreeStyle™ HEK293-F cells using transfection reagents like FectoPRO DNA Transfection Reagent. Purify the resultant antibodies using protein G chromatography and validate their binding and neutralizing properties compared to the parental mouse antibody .

This comprehensive approach ensures the development of humanized antibodies that maintain critical functional properties while reducing potential immunogenicity for research and therapeutic applications.

How does the timing and dosage of passive antibody administration influence efficacy in viral infections, and what implications does this have for HAdV55 research?

The timing and dosage of passive antibody administration significantly impact efficacy in viral infections, as demonstrated by extensive research on passive antibody therapies for COVID-19. These findings have important implications for HAdV55 research:

• Timing considerations: Earlier clinical stage at treatment initiation is highly predictive of efficacy for both monoclonal antibodies (p<0.0001) and convalescent plasma therapy (p=0.030) in preventing disease progression. Prophylaxis or treatment in outpatient settings shows the greatest effects, suggesting that anti-HAdV55 antibody interventions would likely be most effective when administered early in infection or as pre-exposure prophylaxis .

• Dose-response relationship: A significant association exists between antibody dose and efficacy in preventing hospitalization in outpatients (relative risk 0.77; p<0.0001). This suggests that sufficient neutralizing antibody titers are critical for achieving therapeutic outcomes, and dose optimization should be a key consideration in anti-HAdV55 antibody development .

• Antibody potency normalization: When comparing different antibody treatments, it is essential to normalize dose by antibody potency using in vitro neutralization titres. This approach would enable rational comparison of different anti-HAdV55 antibody candidates .

• Variant susceptibility: The efficacy of passive antibody therapy may be substantially reduced against emerging variants, as demonstrated with COVID-19 where some monoclonal antibodies showed less than 30% efficacy against certain Omicron subvariants. This highlights the importance of monitoring HAdV55 genetic diversity and evaluating antibody efficacy against potential viral variants .

These principles establish a framework for the rational design of anti-HAdV55 antibody studies and potential interventions, emphasizing the critical nature of early administration and sufficient dosing to achieve optimal efficacy.

What advanced computational methods can optimize epitope identification and improve antibody-antigen binding predictions for anti-HAdV55 antibodies?

Advanced computational methods can significantly enhance epitope identification and antibody-antigen binding predictions for anti-HAdV55 antibodies through a multi-faceted approach:

• Structural prediction using deep learning: AlphaFold2 implementation in multimer and monomer modes provides high-confidence structural predictions of antibody-antigen complexes. The top-ranked structures based on pLDDT scores offer reliable models for further refinement and analysis .

• CDR conformation optimization: The Antibody_H3 module in Rosetta 3 with default settings can generate and rank thousands of potential CDR3 conformations, which are critical for specific antigen recognition. This approach identifies optimal binding configurations that may not be evident from static models .

• Molecular docking simulations: HADDOCK or equivalent docking platforms enable sophisticated antibody-antigen interaction modeling through:

  • Initial rigid body docking (generating 10,000+ conformations)

  • Selection of top conformations based on energy minimization scores

  • Flexible refinement of promising candidates

  • Energy minimization to identify optimal binding conformations

• Clustering analysis: Dividing conformations into different clusters according to RMSD values identifies families of solutions with similar binding modes, providing insight into alternative binding configurations and their relative stability .

• Integration with experimental validation: Computational predictions should guide targeted experimental approaches such as epitope mapping through site-directed mutagenesis, hydrogen-deuterium exchange mass spectrometry, or cryo-electron microscopy to validate and refine binding models.

These advanced computational approaches, when integrated with experimental validation, provide a powerful platform for optimizing anti-HAdV55 antibody design and understanding the molecular basis of neutralization.

How can antibody profiling technologies be adapted from other research areas to enhance HAdV55 antibody development?

Recent advances in global antibody profiling strategies, particularly those developed for autoimmune conditions like systemic sclerosis (SSc), can be adapted to enhance HAdV55 antibody development:

• DEEP SEQ proteomics platform: Implement automated DEEP SEQ MS platforms for comprehensive antibody profiling. This approach could be modified by constructing antigen pools using lysates from cell lines infected with HAdV55, providing a diverse array of viral antigens in their native conformation .

• Multiplexed antigen-antibody enrichment: Adapt the method of coincubating global antibodies with antigen pools followed by immunoprecipitation using protein A/G beads. This approach could identify novel anti-HAdV55 antibodies from convalescent patient samples or immunized animals .

• Quantitative proteomics analysis: Perform in-solution on-bead trypsin digest of immunoprecipitated complexes followed by peptide labeling and quantitative proteomics analysis to identify specific antibody-antigen interactions of interest .

• Multi-platform validation: Employ multiple orthogonal methods for validation, such as ELISA and microarray analysis, to confirm the specificity and sensitivity of identified antibodies. This multi-platform approach increases confidence in results and reduces platform-specific biases .

• Dilution-based multiplex suspension arrays: Implement technologies that extend the dynamic range of antibody detection to seven orders of magnitude, allowing precise quantification of both high and low abundant antibody specificities in the same sample. This would be particularly valuable for understanding the diversity of anti-HAdV55 antibody responses .

Adaptation of these advanced profiling technologies would significantly enhance the discovery and characterization of novel anti-HAdV55 antibodies with potential diagnostic and therapeutic applications.

What cell-based assays provide the most reliable assessment of anti-HAdV55 antibody neutralizing capacity?

Cell-based assays for evaluating the neutralizing capacity of anti-HAdV55 antibodies require careful methodological considerations to ensure reliability and reproducibility:

• Cell line selection: A549 cells (human alveolar epithelial cells) represent an optimal model system for HAdV55 neutralization assays due to their susceptibility to adenovirus infection and relevance to respiratory pathogenesis. These cells should be maintained at 85-95% confluence for optimal assay performance .

• Virus-antibody neutralization protocol:

  • Seed A549 cells (2.5 × 10^5 cells/mL) in 96-well plates and incubate overnight at 37°C in 5% CO₂

  • Prepare serial two-fold dilutions of purified antibodies in DMEM

  • Mix 50 μL of each antibody dilution with 50 μL of HAdV55 at a standardized concentration (100 TCID₅₀)

  • Incubate virus-antibody mixtures for 1 hour at 37°C

  • Transfer mixtures to the A549 cell monolayers

  • Incubate cells in DMEM with 2% FBS at 37°C for the appropriate infection period

• Readout methods: Multiple complementary approaches provide comprehensive assessment:

  • Microscopic observation of cytopathic effects

  • Cell viability determination using metabolic assays such as CCK-8 (Cell Counting Kit-8)

  • Quantification of viral gene expression through RT-qPCR

  • Detection of viral proteins via immunofluorescence or flow cytometry

• Controls and standardization:

  • Include non-neutralizing antibody controls

  • Incorporate virus-only and cell-only controls

  • Use reference antibodies with known neutralizing activity when available

  • Standardize virus input to ensure reproducibility across experiments

This comprehensive approach provides reliable assessment of neutralizing capacity while minimizing experimental variables that could confound interpretation.

What are the most effective strategies for optimizing the thermal stability of humanized anti-HAdV55 antibodies?

Optimizing the thermal stability of humanized anti-HAdV55 antibodies requires both computational prediction and experimental validation approaches:

• Computational stability prediction:

  • Implement molecular dynamics simulations to identify regions of structural instability

  • Use algorithms specifically designed to predict antibody stability changes upon humanization

  • Apply in silico alanine scanning to identify destabilizing residues

  • Perform virtual mutations based on consensus sequences from stable human antibodies

• Framework selection and optimization:

  • Choose human germline frameworks with inherently high stability profiles

  • Retain key mouse residues that interact with CDRs to maintain proper paratope conformation

  • Introduce stabilizing mutations in framework regions based on computational predictions

• Experimental thermal stability assessment:

  • Differential scanning calorimetry (DSC) to determine melting temperatures (Tm)

  • Differential scanning fluorimetry (DSF) using SYPRO Orange for high-throughput screening

  • Size-exclusion chromatography after thermal challenge to assess aggregation propensity

  • Circular dichroism (CD) spectroscopy to monitor secondary structure changes upon heating

• Formulation optimization:

  • Screen various buffer compositions to identify optimal pH and ionic strength

  • Evaluate the effect of stabilizing excipients (sugars, amino acids, surfactants)

  • Assess freeze-thaw stability under different buffer conditions

  • Determine long-term stability profiles at different temperatures

• Structure-guided engineering:

  • Introduce disulfide bonds at strategic positions to enhance domain stability

  • Optimize charge distribution to reduce repulsive interactions

  • Enhance hydrophobic core packing through targeted mutations

  • Consider post-translational modification sites that might affect stability

By integrating these approaches, researchers can systematically improve the thermal stability of humanized anti-HAdV55 antibodies, enhancing their utility for both research and potential therapeutic applications.

How can researchers optimize screening of phage display libraries to identify the most promising anti-HAdV55 antibody candidates?

Optimizing phage display library screening for anti-HAdV55 antibody discovery requires a systematic approach with several critical considerations:

• Library construction and diversity:

  • Use RNA from immunized mice to ensure a starting repertoire enriched for HAdV55-specific antibodies

  • Apply PCR amplification of variable regions of both heavy and light chains using specialized primer sets

  • Incorporate efficient cloning strategies to maintain diversity during library assembly

  • Validate library diversity through next-generation sequencing before screening

• Target preparation strategies:

  • Purify HAdV55 virions under conditions that preserve native epitopes

  • Consider alternative antigen formats including recombinant viral proteins for epitope-focused selection

  • Implement negative selection steps using related adenovirus serotypes to enhance specificity

  • Biotinylate target antigens for streptavidin-based capture when appropriate

• Selection protocol optimization:

  • Implement a solid-phase screening strategy using purified HAdV55 coated onto immunotubes

  • Employ blocking with bovine serum albumin (3% BSA in PBS) to reduce non-specific binding

  • Use phage library aliquots (e.g., 5.0×10^11 phage particles) for selection with appropriate wash conditions

  • Incorporate increasingly stringent washing steps in successive selection rounds

• Enrichment assessment:

  • Monitor enrichment through polyclonal phage ELISA between selection rounds

  • Sequence selected clones after 3-4 rounds to evaluate convergence toward specific sequences

  • Assess binding characteristics of individual clones using monoclonal phage ELISA

  • Evaluate sequence diversity to ensure selection of multiple candidates with distinct binding properties

• Functional screening integration:

  • Implement early functional screening to identify neutralizing versus non-neutralizing binders

  • Develop high-throughput cell-based assays for preliminary neutralization assessment

  • Consider competitive binding assays to identify antibodies targeting distinct epitopes

  • Prioritize candidates based on both binding affinity and functional activity

This comprehensive approach maximizes the probability of identifying high-quality anti-HAdV55 antibody candidates with desired specificity and neutralizing capacity from phage display libraries.

What lessons from clinical studies of passive antibody therapy can inform potential therapeutic applications of anti-HAdV55 antibodies?

Clinical studies of passive antibody therapy, particularly those investigating COVID-19 treatments, provide valuable insights for developing anti-HAdV55 antibody therapeutics:

• Timing is critical: The efficacy of passive antibody therapy is highly dependent on early administration. Randomized controlled trials have consistently shown that earlier clinical stages at treatment initiation are highly predictive of efficacy for both monoclonal antibodies (p<0.0001) and convalescent plasma therapy (p=0.030). This suggests that anti-HAdV55 antibodies would likely be most effective when administered prophylactically or early in infection before severe disease develops .

• Dose-efficacy relationship: A significant association exists between antibody dose and clinical efficacy. Analysis of outpatient COVID-19 treatment revealed a clear relationship between normalized antibody dose and prevention of hospitalization (relative risk 0.77; p<0.0001). This indicates that sufficient dosing of anti-HAdV55 antibodies would be essential for therapeutic success, requiring careful dose-finding studies .

• Variant susceptibility considerations: Emerging viral variants may significantly reduce antibody efficacy, as demonstrated with some COVID-19 monoclonal antibodies showing less than 30% efficacy against certain Omicron subvariants. This highlights the importance of monitoring HAdV55 genetic diversity and developing antibody cocktails or broadly neutralizing antibodies to mitigate resistance .

• Patient selection implications: The heterogeneity in antibody responses observed in population studies suggests that baseline antibody profiling might help identify patients most likely to benefit from passive antibody therapy. Studies of anti-staphylococcal antibodies revealed extensive variability in individual responses that spanned several orders of magnitude, which likely applies to anti-viral antibodies as well .

These clinical insights provide a framework for designing potential therapeutic applications of anti-HAdV55 antibodies, emphasizing early intervention, appropriate dosing, resistance monitoring, and potentially personalized approaches based on individual immune profiles.

How might novel antibody engineering technologies enhance the development of next-generation anti-HAdV55 therapeutics?

Novel antibody engineering technologies offer promising avenues for developing advanced anti-HAdV55 therapeutics with enhanced properties:

• Bispecific antibody platforms: Engineering bispecific antibodies that simultaneously target HAdV55 viral epitopes and recruit immune effector cells could enhance viral clearance through multiple mechanisms. This approach could combine direct neutralization with Fc-mediated effector functions for improved therapeutic efficacy.

• Antibody-drug conjugates (ADCs): Conjugating anti-HAdV55 antibodies with antiviral payloads could enable targeted delivery of antivirals to infected cells, potentially reducing systemic toxicity while increasing local drug concentration at sites of viral replication.

• Fc engineering for extended half-life: Implementing Fc modifications such as the YTE or LS mutations could significantly extend the half-life of anti-HAdV55 antibodies, potentially enabling single-dose prophylaxis with months-long protection, similar to approaches used for respiratory syncytial virus antibodies.

• Structure-guided epitope focusing: Using the computational approaches described for epitope mapping (AlphaFold2, HADDOCK, etc.), researchers could design antibodies specifically targeting conserved, functionally critical epitopes on HAdV55, potentially providing broader protection against viral escape mutants .

• In vivo antibody discovery platforms: Implementing humanized mouse platforms expressing diverse human antibody repertoires could enable direct isolation of fully human anti-HAdV55 antibodies, bypassing the need for subsequent humanization and potentially preserving optimal binding characteristics.

• mRNA-encoded antibody delivery: Rather than administering purified antibodies, delivering mRNA encoding anti-HAdV55 antibodies could enable in vivo production of therapeutic antibodies, potentially providing more durable protection through sustained antibody expression.

These innovative approaches represent promising directions for enhancing the development of next-generation anti-HAdV55 therapeutics with improved efficacy, durability, and resistance profiles.